Compare ETO & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ETO | BWAY |
|---|---|---|
| Founded | N/A | 2003 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 471.2M | 450.8M |
| IPO Year | 2004 | N/A |
| Metric | ETO | BWAY |
|---|---|---|
| Price | $28.43 | $13.77 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $13.25 |
| AVG Volume (30 Days) | 29.5K | ★ 91.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $314.08 |
| Revenue Next Year | N/A | $23.37 |
| P/E Ratio | ★ N/A | $81.98 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $20.05 | $7.84 |
| 52 Week High | $31.11 | $26.63 |
| Indicator | ETO | BWAY |
|---|---|---|
| Relative Strength Index (RSI) | 30.58 | 30.17 |
| Support Level | $28.04 | $11.55 |
| Resistance Level | $28.77 | $17.20 |
| Average True Range (ATR) | 0.51 | 1.13 |
| MACD | -0.20 | -1.20 |
| Stochastic Oscillator | 18.28 | 16.10 |
Eaton Vance Tax-advtgd Global Divid Oppo is a diversified, closed-end management investment company. Its investment objective is to provide a high level of after-tax total return consisting of tax-advantaged dividend income and capital appreciation. The fund pursues its objective by investing in dividend-paying common and preferred stocks. The portfolio of investments consists of capital markets, chemicals, diversified, beverages, banks, electric utilities, oil, gas and consumable fuels, personal products, and other areas.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.